Menu
Search
|

Menu

Close
X

Akcea Therapeutics Inc AKCA.OQ (NASDAQ Stock Exchange Global Select Market)

28.93 USD
-- (--)
As of Mar 20
chart
Previous Close 28.93
Open --
Volume --
3m Avg Volume 83,588
Today’s High --
Today’s Low --
52 Week High 40.60
52 Week Low 17.74
Shares Outstanding (mil) 89.43
Market Capitalization (mil) 2,587.30
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.20 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
65
FY17
43
FY16
0
EPS (USD)
FY18
-2.720
FY17
-3.397
FY16
-2.881
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
39.89
8.99
Price to Book (MRQ)
vs sector
9.34
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
0.00
17.49
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-97.14
12.11
Return on Equity (TTM)
vs sector
-101.60
13.22

EXECUTIVE LEADERSHIP

Christopher Gabrieli
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Sarah Boyce
President, Director, Since 2018
Salary: --
Bonus: --
Paula Soteropoulos
Chief Executive Officer, Director, Since 2018
Salary: $436,324.00
Bonus: $351,545.00
Michael Maclean
Chief Financial Officer, Since 2017
Salary: $127,154.00
Bonus: $118,970.00
Jeffrey Goldberg
Chief Operating Officer, Since 2015
Salary: $319,982.00
Bonus: $220,788.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

22 Boston Wharf Rd Fl 9
BOSTON   MA   02210-1838

Phone: +1617.2070202
Site: akceatx.com/

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

SPONSORED STORIES